anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: We evaluate morphological and functional correlations in patients with acute central serous chorioretinopathy (CSC).
METHODS: A prospective study was conducted on 50 patients with an acute CSC episode lasting less than 3 months. At baseline, assessments included optical coherence tomography (OCT), best-corrected visual acuity (BCVA), contrast sensitivity (CS), microperimetry (MP), and multifocal electroretinography (mfERG). A correlation analysis between OCT morphological parameters (maximal subretinal fluid height (SRF), central retinal thickness (CRT), and macular volume (MV)) and functional parameters was conducted on the affected eye for each patient.
RESULTS: Among the morphological parameters, SRF showed the strongest correlations with functional parameters (r absolute value range = 0.10-0.70). Weak correlations were observed between BCVA and morphological parameters (r absolute value range = 0.14-0.26). Average retinal sensitivity (MP-A) was the functional parameter displaying the most robust negative correlation with morphological parameters (r absolute value range = 0.61-0.70). In contrast, average contrast sensitivity (CS-A) and mfERG average amplitude density in the first (mfERG-A1) and second (mfERG-A2) ring showed weak to moderate (r absolute value range = 0.35-0.56) yet statistically significantly nonzero correlations.
CONCLUSIONS: SRF and CRT could serve as the most representative morphological proxies for visual function deficit in acute CSC patients. Retinal sensitivity, as measured by MP, may be superior to BCVA in clinical research studies or when an in-depth visual function evaluation is needed.
This is an e-health intervention consisting of 7 online modules. This behavioral intervention combines instruction, hands-on learning, interactive practice opportunities and tailored sessions. Teens learn about asthma, including treatment and triggers, the importance of seeing a medical provider and how they can overcome their specific barriers to seeing a medical provider, how they can talk to their parents about their asthma, and how they can care for their asthma, including managing stress and triggers. They also receive personalized feedback throughout the intervention and guidance on navigating the health care system.
In Surat city of Gujarat, India, female sex workers (FSW)-based targeted interventions (TI) and community-based organizations (CBO) have been functioning since 1998. To document the impact of the COVID-19 lockdown (March-May 2020) on FSWs and STI/RTI/HIV preventive measures provided through TI/CBOs in Surat city, sequential, explanatory mixed-methods design was used. We conducted a desk review of quarterly programmatic data (2018-2020) of four TIs and CBOs and interviewed of 221 FSWs to study pre- and post-lockdown socioeconomic conditions, engagement in sex work, health services during COVID-19 lockdown and coping strategies, followed by five focus group discussions of FSWs and TI/CBO project staff. Study identified four major themes: reasons for working as a FSW during COVID-19 lockdown, entry to sex work during or as a consequence of lockdown, exploitation of FSWs during lockdown, and challenges of TI and CBOs in service provision in pandemic situation. Number of new registrations and STI/RTI detection increased immediately after lockdown. TI/CBO and other NGOs working for women welfare must build financial independence by training them in microeconomics, savings, and entrepreneurship. TI/CBO staff must also include experts in finance or business, trained in emergency response. The presence of strong TI/CBO network facilitated prompt delivery of essential commodities and financial aid to FSWs. However, laboratory and screening services were hampered, which warrants need of introducing self-test kits. In backdrop of decrease in condom distribution, continuation of sex work during lockdown and disruption of routine HIV/STI/RTI screening facilities, our study also recommends intensified HIV/STI/RTI screening among FSWs.
In order to solve the problem of adverse effect existing in the existing anticancer medicine, the invention provides a compound preparation with the auxiliary function of anticancer. The compound preparation consists of a red ginseng extract and a Shen Qi polysaccharide extract (astragalus and lanceolata are extracted according to a certain proportion). The content of total ginsenoside in the red ginseng extract is more than 80 percent and the content of total polysaccharide in the Qi Shen polysaccharide extract is also more than 80 percent. Studies show that the ginsenoside is the mixture of tens of saponin and has the effects of immunity improvement and anticancer, so that the ginsenoside can be used as the auxiliary medicine for anticancer. And the polysaccharide also has the effect of improving immunity. Immunopotentiators, such as Shen Qi righting injection, consisting of the astragalus and the lancelolata, are on the market now. Two extracts are prepared according to a certain proportion, which does not mean that two extracts are combined easily, so the extracts can have remarkable synergistic effect. The extracts can be made into a capsule, a tablet, the injection or oral liquid with different excipients.
FIELD: medicine. ^ SUBSTANCE: treatment or prevention of osteoporosis is ensured by introduction of a pharmaceutical composition containing approximately 150 mg of bisphosphonic acid. Treatment is administered once a month within one day. As bisphosphonic acid, risedronic acid is used preferentially. ^ EFFECT: invention allows improving clinical effectiveness and preventing by-effects in comparison with more frequent introduction of bisphosphononates. ^ 6 cl, 1 tbl, 1 ex
Lower limb (infrainguinal) revascularization surgeries are performed for patients with blood flow occlusion, with the goals of improving pain and function. Graft patency is associated with higher quality of life scores. However, open lower limb revascularization is associated with a significant risk of graft failure. Multiple anesthesia options exist for elective open lower limb revascularization, including general and regional (spinal, epidural, peripheral nerve block). The literature has shown mixed results regarding the superiority of regional anesthesia over general anesthesia for morbidity and mortality. In this study, we will analyze data from the multicenter National Surgical Quality Improvement Program (ACS NSQIP®) to assess the association between regional anesthesia (RA) and graft outcomes, as compared to general anesthesia (GA).Our primary objective is to determine for patients undergoing elective open lower limb revascularization, whether RA (spinal, epidural, and peripheral nerve block), compared to GA or general anesthesia with regional anesthesia (GA+RA), is associated with higher rates of patent graft within 30 days postoperatively (primary outcome). Our secondary outcomes are major reintervention, amputation, bleeding requiring transfusion or secondary procedure, venous thromboembolism (VTE), myocardial infarction (MI) or stroke, pneumonia, discharge destination, postoperative length of stay, readmission rate, and death, all within 30 days postoperatively. There will be two composite outcomes: thromboembolism, and morbidity and mortality. We hypothesize that the use of RA is associated with increased graft patency after elective lower limb revascularization compared to GA. Compared to GA, RA is associated with decreased rates of major reintervention, amputation, death (30 days), bleeding requiring transfusion or secondary procedure, VTE, MI or stroke, pneumonia, mortality, composite thromboembolism, and composite morbidity and mortality.; Compared to GA, RA is associated with increased rates of discharge destination being home.
The "treatment as usual" \[TAU\] group meets a CPAP technician at the sleep clinic, who provides the participant with a CPAP device and fits the mask. The will also receive a follow-up visit with the same technician for technical support, mask changes or alterations if needed after an initial 7 to 14-day at home CPAP trial.
A composition comprising amnion homogenate in admixture with a biologically acceptable excipient is provided. Preferably the amnion homogenate comprises homogenised amnion-containing donor tissue and a liquid medium. The excipient is preferably a hydrophilic polymeric material such as a polysaccharide or polysaccharide-based gel, in particular a hydrogel. Preferably the excipient comprises one or more water soluble polymeric materials such as collagen, gelatin, alginate, chitosan, dextran and glycosaminoglycan, and/or one or more water insoluble polymeric materials, such as cotton, rayon, polyester and cellulose. The composition preferably has a viscosity of at least about 1000 centipoise. A device comprising the amnion homogenate composition and a component scaffold to which the composition is applied or into which the composition is infused is provided. The composition may be a wound dressing, a scar dressing, a topical hydrogel or a topical ointment. A method of manufacturing the amnion homogenate composition is also outlined comprising the steps of: providing a quantity of placental donor tissue that comprises amnion; homogenising the donor tissue in order to produce an amnion homogenate; and admixing the amnion homogenate with a biologically acceptable excipient. The amnion homogenate composition is useful in the treatment of wounds, improving the appearance of skin and/or treating a skin condition.
Use of cationic cyanine derivative (I) as an agent for coloring keratin fibers, preferably human keratin fibers and/or for brightening of optical fibers, is claimed. Use of cationic cyanine derivative of formula (I) as an agent for coloring keratin fibers, preferably human keratin fibers and/or for brightening of optical fibers, is claimed. A : 5-12 membered aromatic heterocycle comprising at least a cationic charge on nitrogen atom and comprising optionally one or more other heteroatoms of N, O or S, where the heterocycle is optionally substituted and/or condensed with one or more aromatic cycles; B 1alkylene group CH 2or (CH 2) 2; either R 1H, halo, OH, 1-24C alkyl interrupted by one or more heteroatoms and substituted, 1-24C alkoxy interrupted by one or more heteroatoms and substituted, non-substituted amino group (mono- or disubstituted by 1-24C alkyl, interrupted by heteroatoms and substituted); or CR 16-30C (non)aromatic cycle or 5-12 membered heterocycle comprising one or more heteroatoms, where the cylce or heterocycle is optionally substituted and/or condensed; R 21-24C alkoxy, 1-24C alkyl (both interrupted by one or more heteroatoms and/or substituted), H or halo; either R 3H, optionally substituted 1-6C alkyl interrupted by one or more heteroatoms or carbonyl group; and R 4optionally substituted 1-24C alkyl interrupted by one or more heteroatoms or carbonyl group and/or by one or more heterocycles, or optionally substituted aryl; or NR 4, NR 3optionally substituted 5-10 membered heterocycle comprising optionally one or more heteroatoms other then N atom carrying R 4; and X ->inorganic or organic anion. Independent claims are included for: (1) a cosmetic composition comprising one or more direct dyes in a coloring medium; (2) a method for the treatment of keratin fibers, preferably human keratin fibers comprising applying the composition on dry or wet keratin fibers for a sufficient time to obtain the color, then rinsing, washing optionally using shampoo, again rinsing and drying the fibers; (3) a device with several compartments or coloring kit comprising a first compartment comprising the cosmetic composition and a second compartment comprising a composition containing one or more oxidizing agents; and (4) a cationic cyanine derivative of formula (II). R 3H; and R 6, R 71-24C alkyl interrupted by one or more heteroatoms and substituted. [Image] [Image].
The invention discloses wall-broken ganoderma pellets, which include raw materials of inner components and a coating. The inner components comprise wall-broken ganoderma powder, carbomer or polyvinylpyrrolidone K30, ethyl cellulose, stearic acid and microcrystalline cellulose. The coating includes talcum powder, a plasticizer and purified water. Further disclosed is a preparation method of wall-broken ganoderma pellets. According to the pellets, the dissolution rate of effective components and the absorption effect of effective components in the body are improved, and the bioavailability is improved. An ideal drug-release rate can be obtained to achieve an anticipative blood-drug level, and the phenomenon of peaks and valleys is overcome. The pellets can provide a long action time.
PURPOSE:To obtain a photopolymerization type dental adhesive having excellent bond strength and strength, containing H-phenylglycine as a reducing agent, dl-camphorquinone as a photosensitizer. adhesion promoting monomer and a base monomer as main components. CONSTITUTION:A dental adhesive consisting of 0.3-0. 6wt.% H-phenylglycine as a reducing agent, 0.5-0.7wt.% dl-camphorquinone as a photosensitizer, 0.5-5.0wt.% adhesion promoting monomer (e.g., 4-methacryloxyethyltrimellitic acid) and 93-99wt.% base monomer (preferably triethylene glycol dimethacrylate). The adhesive does not particularly require a solvent but may optionally use a solvent such as ketone or alcohol solvent. when the adhesive is applied the teeth, the teeth are pretreated with EDTA3-2, etc., and coated with the adhesive, which is irradiated with light rays for 20-60seconds.
NEW MATERIAL:1,4-Benzoquinone derivatives, expressed by formula I (n is 9 when R is H, and is 7 when R is hydroxyl group), expressed by formula II (the sum of l and m is 14), and having 69.5-70.5 deg.C and expressed by formula III, and having 88-90 deg.C melting point. EXAMPLE:5-Methyoxy-8-(cis-10-pentadecenyl)-1,4-benzoquinone. USE:Useful as a preventing and treating agent for asthma, inflammations, allergies, etc., having inhibitory action on arachidonic acid 5-lipoxygenase, and further useful as a preventing and treating agent for hypertension, cerebral apoplexy, cardiac insufficiency, immunity insufficiency, etc. with low toxicity. PREPARATION:For example, Ardisia japonica Bl. which is a plant of the famliy Myrsinaceae or Ardisia sieboldii Miq. which is a plant of the family Myrsinaceae is extracted to isolate the compounds expressed by formulas I , and IIand III.
The specific gamma ray constant for technetium Tc-99m is 0.795 R/hr-mCi at 1 cm. The first half-value layer is 0.023 cm of lead (Pb). A range of values for the relative attenuation of the radiation emitted by this radionuclide that results from interposition of various thicknesses of Pb is shown in Table 2. For example, the use of 0.27 cm thickness of Pb will attenuate the radiation emitted by a factor of about 1000.

Table 2. Radiation Attenuation by Lead Shielding

Molybdenum Mo-99 decays to technetium Tc-99m with a molybdenum Mo-99 half-life of 2.75 days, or 66 hours (see Table 3). The physical decay characteristics of molybdenum Mo-99 are such that only 88.6% of the decaying molybdenum Mo-99 atoms form technetium Tc-99m. Generator elutions may be made at any time, but the amount of technetium Tc-99m available will depend on the interval measured from the last elution. Approximately 47% of the maximum available technetium Tc-99m is reached after 6 hours and 95% after 23 hours. To correct for physical decay of molybdenum Mo-99 and technetium Tc-99m, the fractions that remain at selected intervals of time are shown in Tables 3 and 4.

Table 3. Physical Decay Chart; Molybdenum Mo-99, Half-Life 66 Hours

Table 4. Physical Decay Chart; Technetium Tc-99m, Half-Life 6 Hours

*Calibration Time
1489486 Esters of thienobenzopyrans and thiopyranobenzopyrans L S HARRIS H G PARS J C SHEEHAN and R K RAZDAN 5 March 1975 [5 March 1974] 9212/75 Addition to 1386027 Heading C2C Novel compounds of the Formula I wherein n is 0 to 3, m is 0-3 provided m + n is 2 or 3, R 1  is alkyl, R 2  is C 1-20  alkyl, C 3-8  cycloalkylalkyl or alkylcycloalkylalkyl, R 4  is hydrogen or alkyl, R 5  is hydrogen or alkyl and R 3  is in which Y is C 1-8  alkylene, a is 1 to 4, b is 1 to 4, R 6  is hydrogen or alkyl and X is CH 2 , O, S or NR 7  wherein R 7  is hydrogen or alkyl with the proviso that (a) when X is O, S or NR 7 , a and b are both 2 and (b) Y is a branched chain alkylene group and/or at least one of R 4 , R 5  and R 6  is alkyl wherein cycloalkyl and alkylcycloalkyl moieties have 3 to 8 carbon atoms and alkyl groups unless otherwise specified are C 1-6 , and acid addition salts thereof may be prepared by esterification of a compound of the formula X with an acid R 3 OH or a salt thereof in the presence of a slight excess of a carbodiimide. The intermediates of the Formula X are prepared by cyclizing an appropriately substituted oxo-tetrahydrothiopyran carboxylate or oxo-tetra hydrothiophene carboxylate in which the oxo and carboxylate groups are on adjacent carbon atoms of the ring with an R 2  substituted resorcinol to form a thienobenzopyran or thiopyranobenzopyran of the Formula X in which the R 1  radicals together form an oxo group and subsequently reacting this product with an appropriate Grignard reagent. Ethyl 5 - methyl - 3 - oxo - tetrahydrothiophene-2-carboxylate is prepared by reaction of ethyl mercaptoacetate with ethyl crotonate in the presence of sodium ethoxide to yield diethyl - 4 - methyl - 3 - thiahexanediote followed by cyclization using strong base. Ethyl 5,5- dimethyl - 3 - oxo - tetrahydrothiophene - 2 - carboxylate is prepared by a similar method. Methyl 4 - methyl - 3 - oxotetrahydrothiopyran-2-carboxylate is prepared by reacting 2- methyl-4-butyrolactone with methanolic hydrogen bromide to yield methyl 4-bromo-2-methylbutyrate, followed by condensation of the product with methylmercaptoacetate in base to form methyl 4 - (methoxycarbonylmethylthio)- 2- methyl butyrate followed by cyclization using strong base to yield the required compound. 2 - Methyl - 4 - piperidinobutyric acid hydrochloride is prepared by condensation of 4- bromo-2-methyl butyrate with piperidine to yield ethyl - 2 - methyl - 4 - piperidino butyrate followed by treatment with hydrochloric acid. 2,2 - Dimethyl - 4 - piperidino butyric acid hydrochloride is prepared by reaction of 2,2- dimethyl - 4 - butyrolactone with ethanolic hydrogen bromide to yield ethyl 2,2-dimethyl-4- bromobutyrate which with piperidine yields ethyl 2,2 - dimethyl - 4 - piperidinobutyrate which yields the required compound on treatment with hydrochloric acid. Pharmaceutical compositions of the compounds I with the usual excipients show analgesic, antianxiety, tranquillizing, sedative, antidepressant, anti-convulsant and anti-psychotic activity when administered orally or parenterally.
Each participant in this arm will be evaluated by a physical therapist and psychologist. The physical therapist will use the evaluation to create an individually tailored home-based activity program plan. This home-based activity program will be implemented at the 1-month post-operative cardiology clinic appointment. The psychologist will use the evaluation to create an individually tailored motivational interviewing program. The motivational interviewing program will begin approximately 2 weeks after the TAVR procedure.
Lianhua Qingke (LHQK), a traditional Chinese medicine (TCM) used clinically for the treatment of respiratory diseases with acute tracheobronchitis, and cough, has demonstrated promising efficacy in suppressing inflammation, inhibitingmucin secretion, reducing goblet cell hyperplasia andmaintainingairway epithelial integrity. However, its efficacy in managing chronic obstructive pulmonary disease (COPD) progression, particularly virus-induced acute exacerbations of COPD (AECOPD),remains unclear. Here, cigarette smoke (CS)-induced COPD and CS+virus (influenza H1N1)-triggered AECOPD mouse models were employed to evaluated the therapeutic potential of LHQK. The findings demonstrated that LHQK treatment led to significant improved pulmonary function, suppressed pulmonary inflammation, alleviated lung histopathological changes, and preserved airway epithelial integrity in COPD mice. Additionally, LHQK treatment effectively inhibited viral replication in the lungs of AECOPD mice and decreased recruitment of immune cells (M1 macrophages, progenitor-exhausted T cells and CD8 + T cells) to the lungs. Western blot analysis indicated that the therapeutic effects of LHQK are associated with the inhibition ofNF-κB signaling and NLRP3 inflammasome activation. Collectively, these findings elucidate the underlying mechanisms by which LHQK mitigates COPD and AECOPD, thereby supporting its potential as a therapeutic option for individuals afflicted with these conditions.
Patient receive iodinated contrast agent IV and undergo CEM. Patients who have not undergone DBT as part of their screening or diagnostic imaging within 3 month, undergo DBT. Patients medical records are reviewed.
Methods of making, using and applying a composition to an exposed surface are disclosed using a disposable applicator. The method of making the disposable applicator includes forming a back sheet and a liquid permeable substrate. The substrate is secured to the back sheet and a composition is applied to the substrate. The composition is capable of being transferred onto an exposed surface by wiping the substrate against the exposed surface. A seal is formed on at least a portion of the back sheet. The back sheet is then folded upon itself such that the seal extends completely around the substrate to protect the composition. The methods of using and applying a composition to an exposed surface include breaking the seal and opening the back sheet, grasping the back sheet in one hand and wiping the substrate onto the exposed surface.